Overview
- First-phase ELSA data from 17,283 screenings identified 160 children with early-stage type 1 diabetes, 75 with a single autoantibody, and 7 with previously undiagnosed disease requiring immediate insulin.
- NHS Early-Stage Type 1 Diabetes Clinics will be created at 20 UK sites to provide monitoring, education and a clear pathway from screening to insulin care.
- ELSA 2 launches to widen screening to children aged 2–17, with a target of recruiting 30,000 additional participants across new age groups.
- Teplizumab was licensed by the UK regulator in August 2025 to delay insulin dependence, though routine NHS use awaits a spending-watchdog ruling.
- Researchers and charities say earlier detection should cut emergency presentations such as diabetic ketoacidosis and give families time to prepare.